In the past decade, numerous tyrosine kinase inhibitors (TKIs) have been introduced in the
treatment of chronic myeloid leukemia. Given the significant interpatient variability in TKIs …

This observational study analyzed imatinib pharmacokinetics and response in 2478 chronic
myeloid leukemia (CML) patients. Data were obtained through centralized therapeutic drug …

Elucidation of the pathogenesis of chronic myeloid leukemia (CML) and the introduction of
tyrosine kinase inhibitors (TKIs) has transformed this disease from being invariably fatal to …

Dasatinib is the 2nd generation TKI (Tyrosine Kinase Inhibitor) having the potential to treat
numerous forms of leukemic and cancer patients and it is 300 times more potent than …

The ability to monitor the response of metabolic enzymes to drug exposure in individuals is
highly appealing and critical to personalized medicine. Although pharmacogenomics …

Opinion statement Discovery of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) in
the therapy of patients with chronic myeloid leukemia (CML) is perhaps the most popular …

Cancer-associated thrombosis (CAT) is a leading cause of death amongst people with
cancer. Treatment decisions have become increasingly complex with the introduction of …

Although micro‐and macrovascular complications of diabetes are the most important cause
of mortality and morbidity in people with diabetes, it is increasingly recognized that diabetes …

In the last decade, the development of imatinib, a tyrosine kinase inhibitor, has brought
about unprecedented change in the way newly diagnosed, chronic-phase chronic myeloid …

The management of chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors has
evolved chronic myeloid leukemia into a chronic, manageable disease. A patient-centered …